ClinicalTrials.gg
CompletedNCT03037931HEART-FIDUpdated Jul 3, 2024Results posted

Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study

A Phase 3 interventional study of Ferric Carboxymaltose and Placebo in Heart Failure and Iron-deficiency, sponsored by American Regent, Inc.. Completed at 346 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,065
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing ferric carboxymaltose in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. ferric carboxymaltose · Heart Failure.

Enrollment
Largest of 12
3,065 · median 46
Started
2017
with 4 others
Phase 3
4 of 12
1 open now
Registered
6th of 12
by date
Lead sponsor
1 of 12
American Regent, Inc.

Among the 12 studies testing ferric carboxymaltose in Heart Failure, this one has the largest enrollment, is one of 5 that started in 2017, is one of 4 in phase 3, and was the 6th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 12 studies testing ferric carboxymaltose in Heart Failure is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing ferric carboxymaltose in Heart Failure, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency

Read the detailed description

This is a double-blind, multicenter, prospective, randomized, placebo-controlled study to assess the effects of IV FCM compared to placebo on the 12-month rate of death, hospitalization for worsening heart failure, and the 6-month change in 6 minute walk test (6MWT) distance for patients in heart failure with iron deficiency.

After an initial screening period of up to 28 days, eligible participants will be stratified by region and randomized in a 1:1 ratio to FCM or placebo for treatment.

Study drug administration will occur on Day 0 and Day 7 (±2) as an undiluted slow IV push, with additional study visits planned at 3 month intervals, and additional dosing administered every 6 months as applicable. In a subset of sites, a sub-study will be conducted to characterize serum phosphate levels over time in participants with heart failure and iron deficiency after dosing with FCM. For all participants, hematology, ferritin, and transferrin saturation (TSAT), with appropriate safety evaluations, to determine additional treatment, will occur at 6 month intervals.

03

Conditions studied

  • Heart Failure
  • Iron-deficiency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult (≥18 years of age) able to provide signed, written .
  2. Stable heart failure ( II-IV) on maximally-tolerated background therapy (as determined by the site Principle Investigator) for at least 2 weeks prior to randomization.
  3. Able and willing to perform a six-minute walk test (6MWT) at the time of randomization.
  4. Reduced . Assessment must be performed at least 12 weeks after major cardiac surgical intervention including coronary artery bypass graft (CABG), valvular repair/replacement, or cardiac resynchronization therapy (CRT) device implantation.

    a. Left ventricular ejection fraction ≤ 40% obtained during the screening visit OR either of the following i. Historical value of ejection fraction ≤ 40% within 24 months of screening visit ii. Historical value of ejection fraction ≤ 30% within 36 months of screening visit

  5. >9.0 g/dL and \< 13.5 g/dL (females) or \<15.0 g/dL (males) within 28 days of randomization.
  6. Serum ferritin \<100 ng/mL or 100 to 300 ng/mL with TSAT \<20%.Patients with screening ferritin \<15 ng/mL must have documentation of an appropriate evaluation, as determined by the Principle Investigator, within 3 months of screening and prior to randomization.
  7. Either documented hospitalization for heart failure within 12 months of enrollment or elavated N-terminal-pro-brain natriuretic peptide (NT-proBNP) within 90 days of randomization. a. For patients in normal sinus rhythm: N-terminal-pro-brain natriuretic peptide (NT- proBNP) > 600 pg/mL (or BNP >200 pg/mL) . b . For patients in atrial fibrillation: NT-proBNP >1000 pg/mL (or BNP >400 pg/mL) .

Exclusion criteria

Exclusion Criteria:

  1. Known reaction to any component of FCM.
  2. History of acquired iron overload, or the recent receipt (within 3 months) of erythropoietin stimulating agent, IV iron therapy, or blood transfusion.
  3. Acute myocardial infarction, acute coronary syndrome, , or stroke within 30 days of enrollment.
  4. Uncorrected severe aortic stenosis, severe valvular regurgitation (except mitral regurgitation due to left ventricular dilatation without planned intervention), or left ventricular outflow obstruction requiring intervention.
  5. Current atrial fibrillation or atrial flutter with a mean ventricular response rate >100 per minute (at rest).
  6. Current or planned mechanical circulatory support or heart transplantation.
  7. Hemodialysis or peritoneal dialysis (current or planned within the next 6 months).
  8. Documented liver disease, or active hepatitis (i.e. or aspartate transaminase >3 times the ).
  9. Current or recent (within 3 years) with exception of basal cell carcinoma or squamous cell carcinoma of the skin, or cervical intraepithelial neoplasia.
  10. Active gastrointestinal bleeding.
  11. Female participant of who is pregnant, lactating, or not willing to use adequate precautions during the study and for up to 5 days after the last scheduled dose of study medication.
  12. Inability to return for follow up visits within the necessary windows
  13. Concurrently in a study with product.
  14. No participants with Current Coronavirus Disease-19 (COVID-19) Infection into the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,065 participants (actual)

Study arms

  • Active comparator
    Ferric Carboxymaltose

    Ferric Carboxymaltose 2 doses intravenously of 15mg/kg to a maximum individual dose of 750mg 7 days apart and a maximum combined dose of 1500mg - repeated every 6 months as indicated by the results of iron indices.

    Drug: Ferric Carboxymaltose

  • Placebo comparator
    Placebo

    Normal saline 15ml - 2 doses 7 days apart repeated every 6 months.

    Drug: Placebo

Interventions

  • Intravenous Iron

    Also known as: Injectafer, Ferinject

  • DrugPlacebo

    Normal Saline Solution

    Also known as: Saline solution

06

What researchers measure

Primary outcomes

  1. Number of Deaths

    The number of participants who died out of the total treated group.

    Time frame: 1 year

  2. Number of Hospitalizations for Heart Failure

    The number of participants who were hospitalized for heart failure out of the total treated group.

    Time frame: 1 year

  3. Change in 6MWT (Six Minute Walk Test) Distance

    The change in meters walked at baseline compared to 6 months later.

    Time frame: 6 months

07

Results

Posted Jul 3, 2024

Participant flow

Participant flow — Overall Study
MilestoneFerric CarboxymaltosePlacebo
Started15321533
Completed11231121
Not completed409412
Withdrew: Death354367
Withdrew: Lost to follow-up74
Withdrew: Withdrawal by subject4841

Outcome measures

PrimaryNumber of Deaths

The number of participants who died out of the total treated group.

Time frame:
1 year
Reported as:
Count of participants · Participants
Number of Deaths
ParticipantsFerric CarboxymaltosePlacebo
Number of Deaths131158
PrimaryNumber of Hospitalizations for Heart Failure

The number of participants who were hospitalized for heart failure out of the total treated group.

Time frame:
1 year
Reported as:
Count of participants · Participants
Number of Hospitalizations for Heart Failure
ParticipantsFerric CarboxymaltosePlacebo
Number of Hospitalizations for Heart Failure297332
PrimaryChange in 6MWT (Six Minute Walk Test) Distance

The change in meters walked at baseline compared to 6 months later.

Time frame:
6 months
Reported as:
Mean · unit of measure in meters
Change in 6MWT (Six Minute Walk Test) Distance
unit of measure in metersFerric CarboxymaltosePlacebo
Change in 6MWT (Six Minute Walk Test) Distance8.179 ± 59.9633.979 ± 58.896

Adverse events

Collected over 67.5 months. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ferric Carboxymaltose354/1,532 (23.1%)413/1,532 (27%)424/1,532 (27.7%)
Placebo367/1,533 (23.9%)401/1,533 (26.2%)412/1,533 (26.9%)
Most frequent serious events
Showing 10 of 512
Most frequent serious events
EventFerric CarboxymaltosePlacebo
PneumoniaInfections and infestations57/153235/1533
Acute kidney injuryRenal and urinary disorders46/153240/1533
COVID-19Infections and infestations39/153237/1533
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders23/153221/1533
SepsisInfections and infestations21/153213/1533
CellulitisInfections and infestations12/153221/1533
Urinary Tract InfectionInfections and infestations17/15329/1533
HypotensionVascular disorders17/153214/1533
COVID-19 pneumoniaInfections and infestations11/153217/1533
Respiratory failureRespiratory, thoracic and mediastinal disorders16/153212/1533
Most frequent other events
Showing 10 of 21
Most frequent other events
EventFerric CarboxymaltosePlacebo
PneumoniaInfections and infestations57/153235/1533
Cardiac disordersCardiac disorders50/153252/1533
Acute kidney injuryRenal and urinary disorders46/153240/1533
Nervous system disordersNervous system disorders39/153246/1533
Metabolism and nutrition disordersMetabolism and nutrition disorders44/153245/1533
Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications43/153235/1533
COVID-19Infections and infestations39/153237/1533
General disorders and administration site conditionsGeneral disorders29/153231/1533
Musculoskeletal and connective tissue disorderMusculoskeletal and connective tissue disorders25/153227/1533
Neoplasms benign, malignant and unspecified (incl systs and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps)25/153227/1533

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ferric CarboxymaltosePlaceboTotal
<=18 years000
Between 18 and 65 years5085251033
>=65 years102410082032
Age, Continuous
Age, Continuous(years)Ferric CarboxymaltosePlaceboTotal
Mean68.57 ± 10.9468.57 ± 11.2068.57 ± 11.07
Sex: Female, Male
Sex: Female, Male(Participants)Ferric CarboxymaltosePlaceboTotal
Female5065311037
Male102610022028
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ferric CarboxymaltosePlaceboTotal
Hispanic or Latino85100185
Not Hispanic or Latino144014242864
Unknown or Not Reported7916
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ferric CarboxymaltosePlaceboTotal
American Indian or Alaska Native6511
Asian192140
Native Hawaiian or Other Pacific Islander6511
Black or African American162160322
White132413252649
More than one race235
Unknown or Not Reported131427
Region of Enrollment
Region of Enrollment(participants)Ferric CarboxymaltosePlaceboTotal
Hungary111728
United States6126011213
Czechia141933
Ukraine243217460
Russia5865123
New Zealand4654100
Canada109120229
Latvia134
Poland8387170
Georgia8892180
Australia5951110
Bulgaria195197392
Lithuania13922
Estonia011
Intent-to-treat Analysis Population
Intent-to-treat Analysis Population(Participants)Ferric CarboxymaltosePlaceboTotal
Count of participants112311212244
08

Study locations

346 sites
  • Advanced Cardiovascular LLC
    Alexander City, Alabama 35010, United States
  • Advanced Cardiovascular, LLC
    Auburn, Alabama 36830, United States
  • IMC/Diagnostic & Medical Clinic
    Mobile, Alabama 36604, United States
  • University of South Alabama
    Mobile, Alabama 36617, United States
  • Alaska Heart & Vascular Institute
    Anchorage, Alaska 99508, United States
  • Verde Valley Medical Center
    Cottonwood, Arizona 86326, United States
  • Clinical Research Institute of Arizona, LLC
    Surprise, Arizona 85374, United States
  • Carondelet Heart and Vascular Institute - Cardiology East
    Tucson, Arizona 85710, United States
  • Sparks Regional Medical Center
    Fort Smith, Arkansas 72901, United States
  • NEA Baptist Clinic
    Jonesboro, Arkansas 72401, United States
  • Arkansas Heart Hospital
    Little Rock, Arkansas 72211, United States
  • Westside Medical Associates of Los Angeles
    Beverly Hills, California 90211, United States
  • Harbor-UCLA Medical Center
    Carson, California 90509, United States
  • Valley Clinical Trials, Inc.
    Covina, California 91723, United States
  • TriWest Research Associates, LLC
    El Cajon, California 92020, United States
  • California Heart Specialists
    Huntington Beach, California 92648, United States
  • First Valley Medical Group
    Lancaster, California 93534, United States
  • Healthcare Partners Affiliation Medical Group
    Long Beach, California 90806, United States
  • Axis Clinical Trials
    Los Angeles, California 90036, United States
  • St. Joseph Heritage-Healthcare
    Mission Viejo, California 92691, United States
  • Radin Cardiovascular Medical Group, Inc.
    Newport Beach, California 92663, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Pasadena Clinical Research
    Pasadena, California 91105, United States
  • Eugene Soroka, MD Inc.
    Port Hueneme, California 93041, United States
  • VA San Diego Health Care System
    San Diego, California 92161, United States
  • Interventional Cardiology Medical Group
    West Hills, California 91307, United States
  • South Denver Cardiology Associates, PC
    Littleton, Colorado 80120, United States
  • Danbury Hospital
    Danbury, Connecticut 06810, United States
  • Stamford Hospital
    Stamford, Connecticut 06904, United States
  • Christiana Care
    Newark, Delaware 19718, United States
  • Alfieri Cardiology
    Wilmington, Delaware 19803, United States
  • Cardiology Associates of South Florida
    Boynton Beach, Florida 33472, United States
  • Cardiovascular & Vein Center of Florida
    Bradenton, Florida 34209, United States
  • Innovative Research of West Florida, Inc.
    Clearwater, Florida 33756, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Riverside Clinical Research
    Edgewater, Florida 32132, United States
  • Memorial Regional Hospital
    Hollywood, Florida 33021, United States
  • St. Vincent's Healthcare - Riverside
    Jacksonville, Florida 32204, United States
  • UF Health Jacksonville
    Jacksonville, Florida 32209, United States
  • St. Vincent's Healthcare - Southside Recruiting
    Jacksonville, Florida 32216, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • Empire Clinical Research, LLC
    Miami Lakes, Florida 33016, United States
  • ProLive Medical Research
    Miami, Florida 33130, United States
  • Cordova Research Institute, LLC
    Miami, Florida 33155, United States
  • Med-Care Research
    Miami, Florida 33165, United States
  • ITB Research
    Miami, Florida 33173, United States
  • Vista Health Research
    Miami, Florida 33176, United States
  • Florida Hospital Transplant Institute
    Orlando, Florida 32804, United States
  • Cardiology Partners Clinical Research Institute
    Palm Beach Gardens, Florida 33410, United States
  • Springfield Medical Center
    Panama City, Florida 32401, United States
  • Broward Research Center
    Pembroke Pines, Florida 33024, United States
  • South Florida Research Solutions, LLC
    Pembroke Pines, Florida 33026, United States
  • Cardiology Consultants
    Pensacola, Florida 32501, United States
  • Avanza Medical Research Center
    Pensacola, Florida 32503, United States
  • Professional Health Care of Pinellas
    Saint Petersburg, Florida 33713, United States
  • Indian River Medical Center
    Vero Beach, Florida 32960, United States
  • Cardiology Partners Clinical Research Institute
    Wellington, Florida 33449, United States
  • Piedmont Heart Institute - Athens
    Athens, Georgia 30606, United States
  • Piedmont Heart Institute
    Atlanta, Georgia 30309, United States
  • University Cardiology Associates, LLC
    Augusta, Georgia 30901, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Piedmont Heart Institute Fayetteville
    Fayetteville, Georgia 30214, United States
  • Georgia Arrhythmia Consultants and Research Institute
    Macon, Georgia 31201, United States
  • Mercer University
    Macon, Georgia 31201, United States
  • Atlanta Vanguard Research Institute
    Smyrna, Georgia 30082, United States
  • Saint Luke's Boise Medical Center
    Boise, Idaho 83712, United States
  • Mount Sinai Hospital Medical Center - Department of Cardiology
    Chicago, Illinois 60608, United States
  • Medicoricium, LLC
    Fairview Heights, Illinois 62208, United States
  • Parkview Research Center
    Fort Wayne, Indiana 46845, United States
  • Franciscan Physician Network - Indiana Heart Physicians
    Indianapolis, Indiana 46237, United States
  • St. Vincent Medical Group
    Indianapolis, Indiana 46260, United States
  • Indiana University Health Ball Memorial Hospital, Inc.
    Muncie, Indiana 47303, United States
  • Reid Physician Associates / Reid Health
    Richmond, Indiana 47374, United States
  • Beacon Medical Group Advanced Cardiovascular Specialists
    South Bend, Indiana 46601, United States
  • Alexandria Cardiology Clinic
    Alexandria, Louisiana 71301, United States
  • Heart Clinic of Hammond
    Hammond, Louisiana 70403, United States
  • Cardiovascular Institute of the South
    Houma, Louisiana 70360, United States
  • Tulane Heart & Vascular Institute
    New Orleans, Louisiana 70112, United States
  • Ochsner Health System
    New Orleans, Louisiana 70121, United States
  • Louisiana Heart Center
    Slidell, Louisiana 70458, United States
  • Maine Medical Partners Maine Health Cardiology
    Scarborough, Maine 04074, United States
  • Anne Arundel Health System Research Institute
    Annapolis, Maryland 21401, United States
  • Sinai Hospital of Baltimore
    Baltimore, Maryland 21215, United States
  • Suburban Hospital
    Bethesda, Maryland 20814, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • NECCR Prima Care Research, LLC
    Fall River, Massachusetts 02721, United States
  • Genesys Regional Medical Center
    Grand Blanc, Michigan 48439, United States
  • Western Michigan University Homer Stryker M.D. School of Medicine
    Kalamazoo, Michigan 49008, United States
  • Michigan CardioVascular Institute at Covenant Medical Center
    Saginaw, Michigan 48602, United States
  • Allina Health System, dba Abbott Northwestern Hospital
    Minneapolis, Minnesota 55407, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Cardiology Associates Research, LLC
    Tupelo, Mississippi 38801, United States
  • North Kansas City Hospital
    North Kansas City, Missouri 64116, United States
  • St. Louis Heart & Vascular, PC
    Saint Louis, Missouri 63136, United States
  • Nebraska Heart Institute
    Lincoln, Nebraska 68526, United States
  • CHI Health Research Center
    Omaha, Nebraska 68124, United States
  • University Medical Center of Southern Nevada
    Las Vegas, Nevada 89102, United States
  • Red Rock Clinical Research, LLC
    Las Vegas, Nevada 89146, United States
  • Monmouth Cardiology Associates, LLC
    Eatontown, New Jersey 07724, United States

Showing the first 100 of 346 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mentz RJ, Ambrosy AP, Ezekowitz JA, Lewis GD, Butler J, Wong YW, De Pasquale CG, Troughton RW, O'Meara E, Rockhold FW, Garg J, Samsky MD, Leloudis D, Dugan M, Mundy LM, Hernandez AF; HEART-FID Trial Investigators. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. Circ Heart Fail. 2021 May;14(5):e008100. doi: 10.1161/CIRCHEARTFAILURE.120.008100. Epub 2021 May 18. PubMed 34003690 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Feb 2023, 70 months.

Results were first posted in Jul 2024, 1 year 5 months after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 70 months is above that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2017
First posted
Jan 31, 2017
StartActual
Mar 15, 2017
Primary completionActual
Feb 2, 2023
CompletionActual
Feb 2, 2023
Results first posted
Jul 3, 2024
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03037931
Collaborators
Duke Clinical Research Institute
Responsible party
Sponsor
First posted
Jan 31, 2017
Start date
Mar 15, 2017
Primary completion
Feb 2, 2023
Completion
Feb 2, 2023
Results posted
Jul 3, 2024
Last update
Jul 3, 2024

Study contacts

Adrian F Hernandez, MD
study chair · Duke Clinical Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion